NCT02657005 2025-02-12
TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Oncternal Therapeutics, Inc
Phase 1/2 Terminated
Oncternal Therapeutics, Inc
Bayer
Bristol-Myers Squibb
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)